4 years ago

Pneumagen Secures £3.8 Million to Advance Development of Pan-Antiviral Drug

  • Pneumagen, a UK-based clinical-stage biotech company, has raised £3.8 million in funding co-led by existing investors Thairm Bio and Scottish Enterprise

  • The company plans to use the funds to advance clinical development and manufacturing of its lead product Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs)

  • This brings Pneumagen's total capital secured to date to approximately £14 million.

      • ProblemHealthcare

      "Viral respiratory tract infections (RTIs) like influenza, RSV and COVID-19 are a major health concern, causing significant morbidity and mortality. Current treatments are often ineffective or have side effects."

      Solution

      "Pneumagen is developing Neumifil, an intranasal drug that targets a broad range of RTIs by directly binding and preventing the entry of viruses into the lungs. Neumifil acts by stopping viruses at the site of infection, reducing their ability both to enter cells and to migrate to the lungs."

      Covered on